- Esperion (ESPR) recently reported mixed Q2 earnings with a beat on EPS and miss on revenue. The earnings were not enough for the market and ESPR continues lower.
- The company revealed that NEXLETOL and NEXLIZET had a strong quarter with a 67% increase in net revenue and a 28% increase in prescriptions.
- My ESPR strategy of remaining very active in managing my position has worked out well. I plan on remaining nimble while we wait for the sellers to tire out.
For further details see:
Esperion: Remaining Nimble As The Share Price Remains Under Pressure Following Mixed Q2 Earnings